CDXC (ChromaDex Corp.) התחייבויות שוטפות של החברה

The price evolution of ChromaDex Corporation (CDXC), which specializes in innovative food components, serves as an indicator of market confidence. Effective management ensures the transparency of Niagen patents and proficiency in B2B sales, while Rob Fried's strategic control strengthens margins through global distribution. The current metric stands at 0.00, as the business contends with a fierce battle for consumer loyalty within the longevity supplements segment.

For the scientific leader in metabolism, ChromaDex Corporation (CDXC), short-term debt measures the volume of obligations maturing within one year, determining the business's liquidity and financial autonomy. By analyzing the company's current liabilities on GURU.Markets, an investor assesses the ability of the Niagen brand to service its passives without compromising the pace of clinical trials, confirming the resilience of the fundamental longevity model.